Cover Image
Market Research Report
Product code 
1036823

Point of Care Testing Market Size By Product, By Technology, By Prescription, By Application, By End-use, COVID-19 Impact Analysis, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2021 - 2027

Published: | Global Market Insights Inc. | 400 Pages | Delivery time: 2-3 business days

Price

Back to Top
Point of Care Testing Market Size By Product, By Technology, By Prescription, By Application, By End-use, COVID-19 Impact Analysis, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2021 - 2027
Published: November 12, 2021
Global Market Insights Inc.
Content info: 400 Pages
Delivery time: 2-3 business days
  • ALL
  • Description
  • Table of Contents
Description

The point of care testing market is projected to witness sturdy expansion by 2027 due to rising prevalence of infectious diseases across the globe. In addition, industry prospects are also likely to be strengthened by the steadily growing geriatric population.

Point-of-care (POC) testing entails performing a diagnostic test outside of a laboratory that delivers a quick and reliable result, assisting in the management and diagnosis of chronic diseases and acute infections.

According to a May 2021 study published in American Chemical Society, the ongoing COVID-19 pandemic has emphasized the importance of large-scale, rapid, and accurate disease diagnosis through effective point-of-care (POC) molecular diagnostic tests.

Moreover, the COVID-19 point of care diagnostics market is rapidly evolving to accommodate soaring demand for decentralized and low-cost diagnostics around the globe. Subsequently, the proliferation of pathology labs and diagnostic services has propelled product penetration in the market in recent years.

The point of care testing market has been segmented based on application, product, end-use, prescription, technology, and region.

In terms of product, the market has further been divided into fecal occult testing products, glucose monitoring, drug-of-abuse (DoA) testing products, cardiometabolic testing products, hematology testing products, infectious disease testing products, cholesterol testing products, coagulation testing products, urinalysis testing products, pregnancy and fertility testing products, tumor/cancer marker testing products, and other products.

The cardiometabolic testing products segment attained a sizable valuation of around USD 3.0 billion in 2020 and is expected to further amass notable gains over the forecast period.

From the technology perspective, the market has been categorized into biosensors, lateral flow assays, solid phase, dipsticks, flow-through, microfluidics, agglutination assays, molecular diagnostics, and immunoassays. The biosensors segment is slated to grow at a considerable pace through the review timeline and hit a valuation of more than USD 15.6 billion by the end of 2027.

With respect to prescription, the market has been bifurcated into prescription-based testing and OTC testing. The point of care market from the prescription-based testing sub-segment is anticipated to expand at a significant pace of 7.7% through the stipulated timeframe.

On the basis of application, the market has been segregated into cancer biomarker testing, cardiometabolic testing, pregnancy testing, infectious disease testing, blood glucose testing, nephrology testing, drug-of-abuse (DoA) testing, and other applications. In 2020, the blood glucose testing sub-segment held a substantial market share of over 42.2% and is set to observe robust expansion through the analysis timeline.

In terms of end-use, the market has been classified into home-care settings, hospitals, research laboratories, diagnostic centers, and others. The home-care setting sub-segment is estimated to reach a valuation of more than USD 13.4 billion by the end of 2027.

From the regional spectrum, the Latin America point of care testing market accounted for a market share of above 5.7% in 2020 and is likely to showcase a sturdy growth trajectory through 2021-2027.

Meanwhile, the Middle East & Africa point of care testing market is expected to exhibit robust growth of over 8.0% through the assessment period.

Table of Contents
Product Code: 3086

Table of Contents

Chapter 1 Methodology

  • 1.1 Market definition
  • 1.2 Base estimates & working
    • 1.2.1 North America
    • 1.2.2 Europe
    • 1.2.3 Asia pacific
    • 1.2.4 Latin America
    • 1.2.5 Middle East & Africa
  • 1.3 Forecast parameters
  • 1.4 Data validation
  • 1.5 Data sources
    • 1.5.1 Secondary
      • 1.5.1.1 Paid sources
      • 1.5.1.2 Unpaid sources
    • 1.5.2 Primary

Chapter 2 Executive Summary

  • 2.1 Point of care testing industry 360 degree synopsis, 2016 - 2027 (USD Million)
    • 2.1.1 Business trends
    • 2.1.2 Product trends
    • 2.1.3 Technology trends
    • 2.1.4 Prescription trends
    • 2.1.5 Application trends
    • 2.1.6 End-use trends
    • 2.1.7 Regional trends

Chapter 3 Point of Care Testing Industry Insights

  • 3.1 Industry segmentation
  • 3.2 Industry landscape, 2016 - 2027
  • 3.3 Industry impact forces
    • 3.3.1 Growth drivers
      • 3.3.1.1 Upward trend in disease prevalence among developing countries
      • 3.3.1.2 Surging number of pathology labs and services equipped with advanced diagnostic equipment in North America
      • 3.3.1.3 Technological advancements
      • 3.3.1.4 Increasing R&D investment
      • 3.3.1.5 Growing geriatric population base globally
    • 3.3.2 Industry pitfalls and challenges
      • 3.3.2.1 Stringent regulatory framework
      • 3.3.2.2 High cost of product development
  • 3.4 Growth potential analysis
    • 3.4.1 By product
    • 3.4.2 By technology
    • 3.4.3 By prescription
    • 3.4.4 By application
    • 3.4.5 By end-use
  • 3.5 COVID-19 impact analysis
  • 3.6 Pricing analysis, by cardiac markers, 2020
  • 3.7 Regulatory landscape
  • 3.8 Technology landscape
  • 3.9 Company share analysis, 2020
    • 3.9.1 Global market share analysis, 2020
    • 3.9.2 North America
    • 3.9.3 Europe
    • 3.9.4 Asia Pacific
    • 3.9.5 Latin America
    • 3.9.6 Middle East and Africa
  • 3.10 Porter's analysis
  • 3.11 Competitive landscape,2020
    • 3.11.1 Company matrix analysis
  • 3.12 PESTEL analysis

Chapter 4 Point of Care Testing Market, By Product

  • 4.1 Key segment trends
  • 4.2 Glucose monitoring
    • 4.2.1 Market size, by region, 2016 - 2027 (USD Million)
    • 4.2.2 Strips
      • 4.2.2.1 Market size, by region, 2016 - 2027 (USD Million)
    • 4.2.3 Meters
      • 4.2.3.1 Market size, by region, 2016 - 2027 (USD Million)
    • 4.2.4 Lancets
      • 4.2.4.1 Market size, by region, 2016 - 2027 (USD Million)
  • 4.3 Cardiometabolic testing products
    • 4.3.1 Market size, by region, 2016 - 2027 (USD Million)
    • 4.3.2 Cardiac marker testing products
      • 4.3.2.1 Market size, by region, 2016 - 2027 (USD Million)
      • 4.3.2.2 High-sensitivity troponin I (hsTnl)
        • 4.3.2.2.1 Market size, by region, 2016 - 2027 (USD Million)
      • 4.3.2.3 Brain natriuretic peptide (BNP)
        • 4.3.2.3.1 Market size, by region, 2016 - 2027 (USD Million)
      • 4.3.2.4 D-dimer
        • 4.3.2.4.1 Market size, by region, 2016 - 2027 (USD Million)
      • 4.3.2.5 Creatine kinase-MB (CK-MB)
        • 4.3.2.5.1 Market size, by region, 2016 - 2027 (USD Million)
      • 4.3.2.6 Myoglobin
        • 4.3.2.6.1 Market size, by region, 2016 - 2027 (USD Million)
      • 4.3.2.7 Others
        • 4.3.2.7.1 Market size, by region, 2016 - 2027 (USD Million)
    • 4.3.3 Blood Gas/Electrolytes testing products
      • 4.3.3.1 Market size, by region, 2016 - 2027 (USD Million)
    • 4.3.4 HBA1C testing products
      • 4.3.4.1 Market size, by region, 2016 - 2027 (USD Million)
  • 4.4 Infectious disease testing products
    • 4.4.1 Market size, by region, 2016 - 2027 (USD Million)
    • 4.4.2 Influenza testing products
      • 4.4.2.1 Market size, by region, 2016 - 2027 (USD Million)
    • 4.4.3 HIV testing products
      • 4.4.3.1 Market size, by region, 2016 - 2027 (USD Million)
    • 4.4.4 Hepatitis C testing products
      • 4.4.4.1 Market size, by region, 2016 - 2027 (USD Million)
    • 4.4.5 Sexually transmitted disease (STD) testing products
      • 4.4.5.1 Market size, by region, 2016 - 2027 (USD Million)
    • 4.4.6 Healthcare-associated Infection (HAI) testing products
      • 4.4.6.1 Market size, by region, 2016 - 2027 (USD Million)
    • 4.4.7 Respiratory infection testing products
      • 4.4.7.1 Market size, by region, 2016 - 2027 (USD Million)
    • 4.4.8 Tropical disease testing products
      • 4.4.8.1 Market size, by region, 2016 - 2027 (USD Million)
    • 4.4.9 Other infectious diseases testing products
      • 4.4.9.1 Market size, by region, 2016 - 2027 (USD Million)
  • 4.5 Coagulation testing products
    • 4.5.1 Market size, by region, 2016 - 2027 (USD Million)
    • 4.5.2 PT/INR testing products
      • 4.5.2.1 Market size, by region, 2016 - 2027 (USD Million)
    • 4.5.3 Activated clotting time (ACT/APTT) testing products
      • 4.5.3.1 Market size, by region, 2016 - 2027 (USD Million)
  • 4.6 Pregnancy and fertility testing products
    • 4.6.1 Market size, by region, 2016 - 2027 (USD Million)
    • 4.6.2 Pregnancy testing products
      • 4.6.2.1 Market size, by region, 2016 - 2027 (USD Million)
    • 4.6.3 Fertility testing products
      • 4.6.3.1 Market size, by region, 2016 - 2027 (USD Million)
  • 4.7 Tumor/Cancer marker testing products
    • 4.7.1 Market size, by region, 2016 - 2027 (USD Million)
  • 4.8 Urinalysis testing products
    • 4.8.1 Market size, by region, 2016 - 2027 (USD Million)
  • 4.9 Cholesterol testing products
    • 4.9.1 Market size, by region, 2016 - 2027 (USD Million)
  • 4.10 Hematology testing products
    • 4.10.1 Market size, by region, 2016 - 2027 (USD Million)
  • 4.11 Drug-of-Abuse (DoA) testing products
    • 4.11.1 Market size, by region, 2016 - 2027 (USD Million)
  • 4.12 Fecal occult testing products
    • 4.12.1 Market size, by region, 2016 - 2027 (USD Million)
  • 4.13 Other products
    • 4.13.1 Market size, by region, 2016 - 2027 (USD Million)

Chapter 5 Point of Care Testing Market, By Technology

  • 5.1 Key segment trends
  • 5.2 Lateral flow assays
    • 5.2.1 Market size, by region, 2016 - 2027 (USD Million)
  • 5.3 Dipsticks
    • 5.3.1 Market size, by region, 2016 - 2027 (USD Million)
  • 5.4 Microfluidics
    • 5.4.1 Market size, by region, 2016 - 2027 (USD Million)
  • 5.5 Molecular diagnostics
    • 5.5.1 Market size, by region, 2016 - 2027 (USD Million)
  • 5.6 Immunoassays
    • 5.6.1 Market size, by region, 2016 - 2027 (USD Million)
  • 5.7 Agglutination assays
    • 5.7.1 Market size, by region, 2016 - 2027 (USD Million)
  • 5.8 Flow-through
    • 5.8.1 Market size, by region, 2016 - 2027 (USD Million)
  • 5.9 Solid phase
    • 5.9.1 Market size, by region, 2016 - 2027 (USD Million)
  • 5.10 Biosensors
    • 5.10.1 Market size, by region, 2016 - 2027 (USD Million)

Chapter 6 Point of Care Testing Market, By Prescription

  • 6.1 Key segment trends
  • 6.2 OTC testing
    • 6.2.1 Market size, by region, 2016 - 2027 (USD Million)
  • 6.3 Prescription-based testing
    • 6.3.1 Market size, by region, 2016 - 2027 (USD Million)

Chapter 7 Point of Care Testing Market, By Application

  • 7.1 Key segment trends
  • 7.2 Cardio metabolic testing
    • 7.2.1 Market size, by region, 2016 - 2027 (USD Million)
  • 7.3 Infectious disease testing
    • 7.3.1 Market size, by region, 2016 - 2027 (USD Million)
  • 7.4 Nephrology testing
    • 7.4.1 Market size, by region, 2016 - 2027 (USD Million)
  • 7.5 Drug-of-Abuse (DoA) testing
    • 7.5.1 Market size, by region, 2016 - 2027 (USD Million)
  • 7.6 Blood glucose testing
    • 7.6.1 Market size, by region, 2016 - 2027 (USD Million)
  • 7.7 Pregnancy testing
    • 7.7.1 Market size, by region, 2016 - 2027 (USD Million)
  • 7.8 Cancer biomarker testing
    • 7.8.1 Market size, by region, 2016 - 2027 (USD Million)
  • 7.9 Other applications
    • 7.9.1 Market size, by region, 2016 - 2027 (USD Million)

Chapter 8 Point of Care Testing Market, By End-use

  • 8.1 Key segment trends
  • 8.2 Hospitals
    • 8.2.1 Market size, by region, 2016 - 2027 (USD Million)
  • 8.3 Diagnostic centers
    • 8.3.1 Market size, by region, 2016 - 2027 (USD Million)
  • 8.4 Research laboratories
    • 8.4.1 Market size, by region, 2016 - 2027 (USD Million)
  • 8.5 Home-care settings
    • 8.5.1 Market size, by region, 2016 - 2027 (USD Million)
  • 8.6 Others
    • 8.6.1 Market size, by region, 2016 - 2027 (USD Million)

Chapter 9 Point of Care Testing Market, By Region

  • 9.1 Key regional trends
  • 9.2 North America
    • 9.2.1 Market size, by country, 2016 - 2027 (USD Million)
    • 9.2.2 Market size, by product, 2016 - 2027 (USD Million)
      • 9.2.2.1 Market size, by glucose monitoring, 2016 - 2027 (USD Million)
      • 9.2.2.2 Market size, by cardiometabolic testing products, 2016 - 2027 (USD Million)
        • 9.2.2.2.1 Market size, by cardiac marker testing product, 2016 - 2027 (USD Million)
      • 9.2.2.3 Market size, by infectious disease testing products, 2016 - 2027 (USD Million)
      • 9.2.2.4 Market size, by coagulation testing products, 2016 - 2027 (USD Million)
      • 9.2.2.5 Market size, by pregnancy and fertility testing products, 2016 - 2027 (USD Million)
    • 9.2.3 Market size, by technology, 2016 - 2027 (USD Million)
    • 9.2.4 Market size, by prescription, 2016 - 2027 (USD Million)
    • 9.2.5 Market size, by application, 2016 - 2027 (USD Million)
    • 9.2.6 Market size, by end-use, 2016 - 2027 (USD Million)
    • 9.2.7 U.S.
      • 9.2.7.1 Market size, by product, 2016 - 2027 (USD Million)
        • 9.2.7.1.1 Market size, by glucose monitoring, 2016 - 2027 (USD Million)
        • 9.2.7.1.2 Market size, by cardiometabolic testing products, 2016 - 2027 (USD Million)
        • 9.2.7.1.2.1 Market size, by cardiac marker testing products, 2016-2027 (USD Million)
        • 9.2.7.1.3 Market size, by infectious disease testing products, 2016 - 2027 (USD Million)
        • 9.2.7.1.4 Market size, by coagulation testing products, 2016 - 2027 (USD Million)
        • 9.2.7.1.5 Market size, by pregnancy and fertility testing products, 2016 - 2027 (USD Million)
      • 9.2.7.2 Market size, by technology, 2016 - 2027 (USD Million)
      • 9.2.7.3 Market size, by prescription, 2016 - 2027 (USD Million)
      • 9.2.7.4 Market size, by application, 2016 - 2027 (USD Million)
      • 9.2.7.5 Market size, by end-use, 2016 - 2027 (USD Million)
    • 9.2.8 Canada
      • 9.2.8.1 Market size, by product, 2016 - 2027 (USD Million)
        • 9.2.8.1.1 Market size, by glucose monitoring, 2016 - 2027 (USD Million)
        • 9.2.8.1.2 Market size, by cardiometabolic testing products, 2016 - 2027 (USD Million)
        • 9.2.8.1.2.1 Market size, by cardiac marker testing products, 2016-2027 (USD Million)
        • 9.2.8.1.3 Market size, by infectious disease testing products, 2016 - 2027 (USD Million)
        • 9.2.8.1.4 Market size, by coagulation testing products, 2016 - 2027 (USD Million)
        • 9.2.8.1.5 Market size, by pregnancy and fertility testing products, 2016 - 2027 (USD Million)
      • 9.2.8.2 Market size, by technology, 2016 - 2027 (USD Million)
      • 9.2.8.3 Market size, by prescription, 2016 - 2027 (USD Million)
      • 9.2.8.4 Market size, by application, 2016 - 2027 (USD Million)
      • 9.2.8.5 Market size, by end-use, 2016 - 2027 (USD Million)
  • 9.3 Europe
    • 9.3.1 Market size, by country, 2016 - 2027 (USD Million)
    • 9.3.2 Market size, by product, 2016 - 2027 (USD Million)
      • 9.3.2.1 Market size, by glucose monitoring, 2016 - 2027 (USD Million)
      • 9.3.2.2 Market size, by cardiometabolic testing products, 2016 - 2027 (USD Million)
        • 9.3.2.2.1 Market size, by cardiac marker testing products, 2016-2027 (USD Million)
      • 9.3.2.3 Market size, by infectious disease testing products, 2016 - 2027 (USD Million)
      • 9.3.2.4 Market size, by coagulation testing products, 2016 - 2027 (USD Million)
      • 9.3.2.5 Market size, by pregnancy and fertility testing products, 2016 - 2027 (USD Million)
    • 9.3.3 Market size, by technology, 2016 - 2027 (USD Million)
    • 9.3.4 Market size, by prescription, 2016 - 2027 (USD Million)
    • 9.3.5 Market size, by application, 2016 - 2027 (USD Million)
    • 9.3.6 Market size, by end-use, 2016 - 2027 (USD Million)
    • 9.3.7 Germany
      • 9.3.7.1 Market size, by product, 2016 - 2027 (USD Million)
        • 9.3.7.1.1 Market size, by glucose monitoring, 2016 - 2027 (USD Million)
        • 9.3.7.1.2 Market size, by cardiometabolic testing products, 2016 - 2027 (USD Million)
        • 9.3.7.1.2.1 Market size, by cardiac marker testing products, 2016-2027 (USD Million)
        • 9.3.7.1.3 Market size, by infectious disease testing products, 2016 - 2027 (USD Million)
        • 9.3.7.1.4 Market size, by coagulation testing products, 2016 - 2027 (USD Million)
        • 9.3.7.1.5 Market size, by pregnancy and fertility testing products, 2016 - 2027 (USD Million)
      • 9.3.7.2 Market size, by technology, 2016 - 2027 (USD Million)
      • 9.3.7.3 Market size, by prescription, 2016 - 2027 (USD Million)
      • 9.3.7.4 Market size, by application, 2016 - 2027 (USD Million)
      • 9.3.7.5 Market size, by end-use, 2016 - 2027 (USD Million)
    • 9.3.8 UK
      • 9.3.8.1 Market size, by product, 2016 - 2027 (USD Million)
        • 9.3.8.1.1 Market size, by glucose monitoring, 2016 - 2027 (USD Million)
        • 9.3.8.1.2 Market size, by cardiometabolic testing products, 2016 - 2027 (USD Million)
        • 9.3.8.1.2.1 Market size, by cardiac marker testing products, 2016-2027 (USD Million)
        • 9.3.8.1.3 Market size, by infectious disease testing products, 2016 - 2027 (USD Million)
        • 9.3.8.1.4 Market size, by coagulation testing products, 2016 - 2027 (USD Million)
        • 9.3.8.1.5 Market size, by pregnancy and fertility testing products, 2016 - 2027 (USD Million)
      • 9.3.8.2 Market size, by technology, 2016 - 2027 (USD Million)
      • 9.3.8.3 Market size, by prescription, 2016 - 2027 (USD Million)
      • 9.3.8.4 Market size, by application, 2016 - 2027 (USD Million)
      • 9.3.8.5 Market size, by end-use, 2016 - 2027 (USD Million)
    • 9.3.9 France
      • 9.3.9.1 Market size, by product, 2016 - 2027 (USD Million)
        • 9.3.9.1.1 Market size, by glucose monitoring, 2016 - 2027 (USD Million)
        • 9.3.9.1.2 Market size, by cardiometabolic testing products, 2016 - 2027 (USD Million)
        • 9.3.9.1.2.1 Market size, by cardiac marker testing products, 2016-2027 (USD Million)
        • 9.3.9.1.3 Market size, by infectious disease testing products, 2016 - 2027 (USD Million)
        • 9.3.9.1.4 Market size, by coagulation testing products, 2016 - 2027 (USD Million)
        • 9.3.9.1.5 Market size, by pregnancy and fertility testing products, 2016 - 2027 (USD Million)
      • 9.3.9.2 Market size, by technology, 2016 - 2027 (USD Million)
      • 9.3.9.3 Market size, by prescription, 2016 - 2027 (USD Million)
      • 9.3.9.4 Market size, by application, 2016 - 2027 (USD Million)
      • 9.3.9.5 Market size, by end-use, 2016 - 2027 (USD Million)
    • 9.3.10 Spain
      • 9.3.10.1 Market size, by product, 2016 - 2027 (USD Million)
        • 9.3.10.1.1 Market size, by glucose monitoring, 2016 - 2027 (USD Million)
        • 9.3.10.1.2 Market size, by cardiometabolic testing products, 2016 - 2027 (USD Million)
        • 9.3.10.1.2.1 Market size, by cardiac marker testing products, 2016-2027 (USD Million)
        • 9.3.10.1.3 Market size, by infectious disease testing products, 2016 - 2027 (USD Million)
        • 9.3.10.1.4 Market size, by coagulation testing products, 2016 - 2027 (USD Million)
        • 9.3.10.1.5 Market size, by pregnancy and fertility testing products, 2016 - 2027 (USD Million)
      • 9.3.10.2 Market size, by technology, 2016 - 2027 (USD Million)
      • 9.3.10.3 Market size, by prescription, 2016 - 2027 (USD Million)
      • 9.3.10.4 Market size, by application, 2016 - 2027 (USD Million)
      • 9.3.10.5 Market size, by end-use, 2016 - 2027 (USD Million)
    • 9.3.11 Italy
      • 9.3.11.1 Market size, by product, 2016 - 2027 (USD Million)
        • 9.3.11.1.1 Market size, by glucose monitoring, 2016 - 2027 (USD Million)
        • 9.3.11.1.2 Market size, by cardiometabolic testing products, 2016 - 2027 (USD Million)
        • 9.3.11.1.2.1 Market size, by cardiac marker testing products, 2016-2027 (USD Million)
        • 9.3.11.1.3 Market size, by infectious disease testing products, 2016 - 2027 (USD Million)
        • 9.3.11.1.4 Market size, by coagulation testing products, 2016 - 2027 (USD Million)
        • 9.3.11.1.5 Market size, by pregnancy and fertility testing products, 2016 - 2027 (USD Million)
      • 9.3.11.2 Market size, by technology, 2016 - 2027 (USD Million)
      • 9.3.11.3 Market size, by prescription, 2016 - 2027 (USD Million)
      • 9.3.11.4 Market size, by application, 2016 - 2027 (USD Million)
      • 9.3.11.5 Market size, by end-use, 2016 - 2027 (USD Million)
  • 9.4 Asia Pacific
    • 9.4.1 Market size, by country, 2016 - 2027 (USD Million)
    • 9.4.2 Market size, by product, 2016 - 2027 (USD Million)
      • 9.4.2.1 Market size, by glucose monitoring, 2016 - 2027 (USD Million)
      • 9.4.2.2 Market size, by cardiometabolic testing products, 2016 - 2027 (USD Million)
        • 9.4.2.2.1 Market size, by cardiac marker testing products, 2016-2027 (USD Million)
      • 9.4.2.3 Market size, by infectious disease testing products, 2016 - 2027 (USD Million)
      • 9.4.2.4 Market size, by coagulation testing products, 2016 - 2027 (USD Million)
      • 9.4.2.5 Market size, by pregnancy and fertility testing products, 2016 - 2027 (USD Million)
    • 9.4.3 Market size, by technology, 2016 - 2027 (USD Million)
    • 9.4.4 Market size, by prescription, 2016 - 2027 (USD Million)
    • 9.4.5 Market size, by application, 2016 - 2027 (USD Million)
    • 9.4.6 Market size, by end-use, 2016 - 2027 (USD Million)
    • 9.4.7 China
      • 9.4.7.1 Market size, by product, 2016 - 2027 (USD Million)
        • 9.4.7.1.1 Market size, by glucose monitoring, 2016 - 2027 (USD Million)
        • 9.4.7.1.2 Market size, by cardiometabolic testing products, 2016 - 2027 (USD Million)
        • 9.4.7.1.2.1 Market size, by cardiac marker testing products, 2016-2027 (USD Million)
        • 9.4.7.1.3 Market size, by infectious disease testing products, 2016 - 2027 (USD Million)
        • 9.4.7.1.4 Market size, by coagulation testing products, 2016 - 2027 (USD Million)
        • 9.4.7.1.5 Market size, by pregnancy and fertility testing products, 2016 - 2027 (USD Million)
      • 9.4.7.2 Market size, by technology, 2016 - 2027 (USD Million)
      • 9.4.7.3 Market size, by prescription, 2016 - 2027 (USD Million)
      • 9.4.7.4 Market size, by application, 2016 - 2027 (USD Million)
      • 9.4.7.5 Market size, by end-use, 2016 - 2027 (USD Million)
    • 9.4.8 Japan
      • 9.4.8.1 Market size, by product, 2016 - 2027 (USD Million)
        • 9.4.8.1.1 Market size, by glucose monitoring, 2016 - 2027 (USD Million)
        • 9.4.8.1.2 Market size, by cardiometabolic testing products, 2016 - 2027 (USD Million)
        • 9.4.8.1.2.1 Market size, by cardiac marker testing products, 2016-2027 (USD Million)
        • 9.4.8.1.3 Market size, by infectious disease testing products, 2016 - 2027 (USD Million)
        • 9.4.8.1.4 Market size, by coagulation testing products, 2016 - 2027 (USD Million)
        • 9.4.8.1.5 Market size, by pregnancy and fertility testing products, 2016 - 2027 (USD Million)
      • 9.4.8.2 Market size, by technology, 2016 - 2027 (USD Million)
      • 9.4.8.3 Market size, by prescription, 2016 - 2027 (USD Million)
      • 9.4.8.4 Market size, by application, 2016 - 2027 (USD Million)
      • 9.4.8.5 Market size, by end-use, 2016 - 2027 (USD Million)
    • 9.4.9 India
      • 9.4.9.1 Market size, by product, 2016 - 2027 (USD Million)
        • 9.4.9.1.1 Market size, by glucose monitoring, 2016 - 2027 (USD Million)
        • 9.4.9.1.2 Market size, by cardiometabolic testing products, 2016 - 2027 (USD Million)
        • 9.4.9.1.2.1 Market size, by cardiac marker testing products, 2016-2027 (USD Million)
        • 9.4.9.1.3 Market size, by infectious disease testing products, 2016 - 2027 (USD Million)
        • 9.4.9.1.4 Market size, by coagulation testing products, 2016 - 2027 (USD Million)
        • 9.4.9.1.5 Market size, by pregnancy and fertility testing products, 2016 - 2027 (USD Million)
      • 9.4.9.2 Market size, by technology, 2016 - 2027 (USD Million)
      • 9.4.9.3 Market size, by prescription, 2016 - 2027 (USD Million)
      • 9.4.9.4 Market size, by application, 2016 - 2027 (USD Million)
      • 9.4.9.5 Market size, by end-use, 2016 - 2027 (USD Million)
    • 9.4.10 Australia
      • 9.4.10.1 Market size, by product, 2016 - 2027 (USD Million)
        • 9.4.10.1.1 Market size, by glucose monitoring, 2016 - 2027 (USD Million)
        • 9.4.10.1.2 Market size, by cardiometabolic testing products, 2016 - 2027 (USD Million)
        • 9.4.10.1.2.1 Market size, by cardiac marker testing products, 2016-2027 (USD Million)
        • 9.4.10.1.3 Market size, by infectious disease testing products, 2016 - 2027 (USD Million)
        • 9.4.10.1.4 Market size, by coagulation testing products, 2016 - 2027 (USD Million)
        • 9.4.10.1.5 Market size, by pregnancy and fertility testing products, 2016 - 2027 (USD Million)
      • 9.4.10.2 Market size, by technology, 2016 - 2027 (USD Million)
      • 9.4.10.3 Market size, by prescription, 2016 - 2027 (USD Million)
      • 9.4.10.4 Market size, by application, 2016 - 2027 (USD Million)
      • 9.4.10.5 Market size, by end-use, 2016 - 2027 (USD Million)
  • 9.5 Latin America
    • 9.5.1 Market size, by country, 2016 - 2027 (USD Million)
    • 9.5.2 Market size, by product, 2016 - 2027 (USD Million)
      • 9.5.2.1 Market size, by glucose monitoring, 2016 - 2027 (USD Million)
      • 9.5.2.2 Market size, by cardiometabolic testing products, 2016 - 2027 (USD Million)
        • 9.5.2.2.1 Market size, by cardiac marker testing products, 2016-2027 (USD Million)
      • 9.5.2.3 Market size, by infectious disease testing products, 2016 - 2027 (USD Million)
      • 9.5.2.4 Market size, by coagulation testing products, 2016 - 2027 (USD Million)
      • 9.5.2.5 Market size, by pregnancy and fertility testing products, 2016 - 2027 (USD Million)
    • 9.5.3 Market size, by technology, 2016 - 2027 (USD Million)
    • 9.5.4 Market size, by prescription, 2016 - 2027 (USD Million)
    • 9.5.5 Market size, by application, 2016 - 2027 (USD Million)
    • 9.5.6 Market size, by end-use, 2016 - 2027 (USD Million)
    • 9.5.7 Brazil
      • 9.5.7.1 Market size, by product, 2016 - 2027 (USD Million)
        • 9.5.7.1.1 Market size, by glucose monitoring, 2016 - 2027 (USD Million)
        • 9.5.7.1.2 Market size, by cardiometabolic testing products, 2016 - 2027 (USD Million)
        • 9.5.7.1.2.1 Market size, by cardiac marker testing products, 2016-2027 (USD Million)
        • 9.5.7.1.3 Market size, by infectious disease testing products, 2016 - 2027 (USD Million)
        • 9.5.7.1.4 Market size, by coagulation testing products, 2016 - 2027 (USD Million)
        • 9.5.7.1.5 Market size, by pregnancy and fertility testing products, 2016 - 2027 (USD Million)
      • 9.5.7.2 Market size, by technology, 2016 - 2027 (USD Million)
      • 9.5.7.3 Market size, by prescription, 2016 - 2027 (USD Million)
      • 9.5.7.4 Market size, by application, 2016 - 2027 (USD Million)
      • 9.5.7.5 Market size, by end-use, 2016 - 2027 (USD Million)
    • 9.5.8 Mexico
      • 9.5.8.1 Market size, by product, 2016 - 2027 (USD Million)
        • 9.5.8.1.1 Market size, by glucose monitoring, 2016 - 2027 (USD Million)
        • 9.5.8.1.2 Market size, by cardiometabolic testing products, 2016 - 2027 (USD Million)
        • 9.5.8.1.2.1 Market size, by cardiac marker testing products, 2016-2027 (USD Million)
        • 9.5.8.1.3 Market size, by infectious disease testing products, 2016 - 2027 (USD Million)
        • 9.5.8.1.4 Market size, by coagulation testing products, 2016 - 2027 (USD Million)
        • 9.5.8.1.5 Market size, by pregnancy and fertility testing products, 2016 - 2027 (USD Million)
      • 9.5.8.2 Market size, by technology, 2016 - 2027 (USD Million)
      • 9.5.8.3 Market size, by prescription, 2016 - 2027 (USD Million)
      • 9.5.8.4 Market size, by application, 2016 - 2027 (USD Million)
      • 9.5.8.5 Market size, by end-use, 2016 - 2027 (USD Million)
  • 9.6 Middle East and Africa
    • 9.6.1 Market size, by country, 2016 - 2027 (USD Million)
    • 9.6.2 Market size, by product, 2016 - 2027 (USD Million)
      • 9.6.2.1 Market size, by glucose monitoring, 2016 - 2027 (USD Million)
      • 9.6.2.2 Market size, by cardiometabolic testing products, 2016 - 2027 (USD Million)
        • 9.6.2.2.1 Market size, by cardiac marker testing products, 2016-2027 (USD Million)
      • 9.6.2.3 Market size, by infectious disease testing products, 2016 - 2027 (USD Million)
      • 9.6.2.4 Market size, by coagulation testing products, 2016 - 2027 (USD Million)
      • 9.6.2.5 Market size, by pregnancy and fertility testing products, 2016 - 2027 (USD Million)
    • 9.6.3 Market size, by technology, 2016 - 2027 (USD Million)
    • 9.6.4 Market size, by prescription, 2016 - 2027 (USD Million)
    • 9.6.5 Market size, by application, 2016 - 2027 (USD Million)
    • 9.6.6 Market size, by end-use, 2016 - 2027 (USD Million)
    • 9.6.7 South Africa
      • 9.6.7.1 Market size, by product, 2016 - 2027 (USD Million)
        • 9.6.7.1.1 Market size, by glucose monitoring, 2016 - 2027 (USD Million)
        • 9.6.7.1.2 Market size, by cardiometabolic testing products, 2016 - 2027 (USD Million)
        • 9.6.7.1.2.1 Market size, by cardiac marker testing products, 2016-2027 (USD Million)
        • 9.6.7.1.3 Market size, by infectious disease testing products, 2016 - 2027 (USD Million)
        • 9.6.7.1.4 Market size, by coagulation testing products, 2016 - 2027 (USD Million)
        • 9.6.7.1.5 Market size, by pregnancy and fertility testing products, 2016 - 2027 (USD Million)
      • 9.6.7.2 Market size, by technology, 2016 - 2027 (USD Million)
      • 9.6.7.3 Market size, by prescription, 2016 - 2027 (USD Million)
      • 9.6.7.4 Market size, by application, 2016 - 2027 (USD Million)
      • 9.6.7.5 Market size, by end-use, 2016 - 2027 (USD Million)
    • 9.6.8 Saudi Arabia
      • 9.6.8.1 Market size, by product, 2016 - 2027 (USD Million)
        • 9.6.8.1.1 Market size, by glucose monitoring, 2016 - 2027 (USD Million)
        • 9.6.8.1.2 Market size, by cardiometabolic testing products, 2016 - 2027 (USD Million)
        • 9.6.8.1.2.1 Market size, by cardiac marker testing products, 2016-2027 (USD Million)
        • 9.6.8.1.3 Market size, by infectious disease testing products, 2016 - 2027 (USD Million)
        • 9.6.8.1.4 Market size, by coagulation testing products, 2016 - 2027 (USD Million)
        • 9.6.8.1.5 Market size, by pregnancy and fertility testing products, 2016 - 2027 (USD Million)
      • 9.6.8.2 Market size, by technology, 2016 - 2027 (USD Million)
      • 9.6.8.3 Market size, by prescription, 2016 - 2027 (USD Million)
      • 9.6.8.4 Market size, by application, 2016 - 2027 (USD Million)
      • 9.6.8.5 Market size, by end-use, 2016 - 2027 (USD Million)

Chapter 10 Company Profiles

  • 10.1 Competitive dashboard
  • 10.2 Abaxis, Inc.
    • 10.2.1 Business overview
    • 10.2.2 Financial data
    • 10.2.3 Product landscape
    • 10.2.4 Strategic outlook
    • 10.2.5 SWOT analysis
  • 10.3 Abbott Laboratories
    • 10.3.1 Business overview
    • 10.3.2 Financial data
    • 10.3.3 Product landscape
    • 10.3.4 Strategic outlook
    • 10.3.5 SWOT analysis
  • 10.4 Accubiotech Co, Ltd.
    • 10.4.1 Business overview
    • 10.4.2 Financial data
    • 10.4.3 Product landscape
    • 10.4.4 Strategic outlook
    • 10.4.5 SWOT analysis
  • 10.5 ACON Laboratories, Inc
    • 10.5.1 Business overview
    • 10.5.2 Financial data
    • 10.5.3 Product landscape
    • 10.5.4 Strategic outlook
    • 10.5.5 SWOT analysis
  • 10.6 Becton, Dickinson and Company
    • 10.6.1 Business overview
    • 10.6.2 Financial data
    • 10.6.3 Product landscape
    • 10.6.4 Strategic outlook
    • 10.6.5 SWOT analysis
  • 10.7 Biolytical Laboratories
    • 10.7.1 Business overview
    • 10.7.2 Financial data
    • 10.7.3 Product landscape
    • 10.7.4 Strategic outlook
    • 10.7.5 SWOT analysis
  • 10.8 BioMrieux SA
    • 10.8.1 Business overview
    • 10.8.2 Financial data
    • 10.8.3 Product landscape
    • 10.8.4 Strategic outlook
    • 10.8.5 SWOT analysis
  • 10.9 Bio-Rad Laboratories, Inc
    • 10.9.1 Business overview
    • 10.9.2 Financial data
    • 10.9.3 Product landscape
    • 10.9.4 Strategic outlook
    • 10.9.5 SWOT analysis
  • 10.10 Danaher Corporation (HemoCue)
    • 10.10.1 Business overview
    • 10.10.2 Financial data
    • 10.10.3 Product landscape
    • 10.10.4 Strategic outlook
    • 10.10.5 SWOT analysis
  • 10.11 Dexcom, Inc
    • 10.11.1 Business overview
    • 10.11.2 Financial data
    • 10.11.3 Product landscape
    • 10.11.4 Strategic outlook
    • 10.11.5 SWOT analysis
  • 10.12 Dragerwerk Ag & Co
    • 10.12.1 Business overview
    • 10.12.2 Financial data
    • 10.12.3 Product landscape
    • 10.12.4 Strategic outlook
    • 10.12.5 SWOT analysis
  • 10.13 LifeScan IP Holdings, LLC
    • 10.13.1 Business overview
    • 10.13.2 Financial data
    • 10.13.3 Product landscape
    • 10.13.4 Strategic outlook
    • 10.13.5 SWOT analysis
  • 10.14 Medtronic
    • 10.14.1 Business overview
    • 10.14.2 Financial data
    • 10.14.3 Product landscape
    • 10.14.4 Strategic outlook
    • 10.14.5 SWOT analysis
  • 10.15 Meridian Bioscience, Inc
    • 10.15.1 Business overview
    • 10.15.2 Financial data
    • 10.15.3 Product landscape
    • 10.15.4 Strategic outlook
    • 10.15.5 SWOT analysis
  • 10.16 Nova Biomedical
    • 10.16.1 Business overview
    • 10.16.2 Financial data
    • 10.16.3 Product landscape
    • 10.16.4 Strategic outlook
    • 10.16.5 SWOT analysis
  • 10.17 Orasure Technologies, Inc
    • 10.17.1 Business overview
    • 10.17.2 Financial data
    • 10.17.3 Product landscape
    • 10.17.4 Strategic outlook
    • 10.17.5 SWOT analysis
  • 10.18 F Hoffmann-La Roche Ltd
    • 10.18.1 Business overview
    • 10.18.2 Financial data
    • 10.18.3 Product landscape
    • 10.18.4 Strategic outlook
    • 10.18.5 SWOT analysis
  • 10.19 Siemens Healthineers
    • 10.19.1 Business overview
    • 10.19.2 Financial data
    • 10.19.3 Product landscape
    • 10.19.4 Strategic outlook
    • 10.19.5 SWOT analysis
  • 10.20 Sysmex Corporation
    • 10.20.1 Business overview
    • 10.20.2 Financial data
    • 10.20.3 Product landscape
    • 10.20.4 Strategic outlook
    • 10.20.5 SWOT analysis
  • 10.21 Trinity Biotech
    • 10.21.1 Business overview
    • 10.21.2 Financial data
    • 10.21.3 Product landscape
    • 10.21.4 Strategic outlook
    • 10.21.5 SWOT analysis